HeartFlow Analysis vs Zio AT ECG Monitoring System
AI Verdict
Choose HeartFlow Analysis if…
Choose HeartFlow Analysis if you need a non-invasive, detailed assessment of coronary artery disease (CAD) severity and its functional impact. This tool is ideal for evaluating patients with suspected CAD based on CT scans, providing insights into stenosis and blood flow dynamics without the need for an invasive angiogram.
View HeartFlow Analysis →Choose Zio AT ECG Monitoring System if…
Choose Zio AT ECG Monitoring System if you require continuous, long-term monitoring for the detection of intermittent or asymptomatic cardiac arrhythmias. This wearable solution is best suited for patients experiencing symptoms like palpitations or syncope, or those at risk for arrhythmias, where extended ECG recording is necessary to capture transient events that might otherwise be missed.
View Zio AT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | HeartFlow Analysis | Zio AT ECG Monitoring System |
|---|---|---|
| Pricing | Contact vendor for pricing | Contact for pricing |
| Deployment | Cloud-based (AWS) | Cloud-based (data analytics and clinician portal) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieHeartFlow Analysis provides AI-powered 3D models and FFRct analysis from CT scans, streamlining complex diagnostic interpretation for clinicians. Zio AT offers a patient-friendly wearable patch for continuous ECG monitoring and a comprehensive clinician portal for reporting. Both aim to simplify complex medical processes for their respective users, making a definitive winner difficult without direct comparative user experience data.
Clinical Value
TieHeartFlow Analysis offers a non-invasive solution for diagnosing coronary artery disease with high diagnostic accuracy, potentially reducing the need for invasive procedures. Zio AT provides continuous, AI-powered ECG monitoring for long-term arrhythmia detection, significantly improving detection rates compared to traditional methods. Both are FDA-cleared and supported by clinical evidence demonstrating substantial benefits in their respective cardiology fields.
Pricing & Value
HeartFlow AnalysisHeartFlow Analysis explicitly mentions Category I CPT codes for FFRct Analysis (75580) and AI-Enabled Quantitative Plaque Analysis (75577 for 2026), with established CMS payment rates, indicating clear and favorable reimbursement pathways. While Zio AT also has Category I CPT codes for its services, HeartFlow's detailed CPT code and reimbursement information, along with studies showing cost-effectiveness by reducing downstream invasive procedures, suggest a more mature and transparent value proposition from a financial perspective for providers.
Enterprise Readiness
TieBoth HeartFlow Analysis and Zio AT ECG Monitoring System are offered by established companies (HeartFlow and iRhythm Technologies, Inc., respectively). Both are FDA-cleared, HIPAA-compliant, provide Business Associate Agreements (BAAs), and utilize cloud-based deployments (AWS for HeartFlow) for scalability and data management. This indicates strong enterprise readiness for both solutions.
Innovation
TieHeartFlow Analysis pioneered the non-invasive assessment of coronary artery disease by combining AI and computational fluid dynamics to derive FFR from CT scans, a significant advancement over traditional invasive methods. Zio AT revolutionized ambulatory ECG monitoring with its long-term wearable patch and AI-powered arrhythmia detection, offering a more patient-friendly and effective diagnostic tool than conventional Holter monitors. Both represent substantial and impactful innovations in cardiovascular diagnostics.
Support & Docs
TieThe provided structured facts do not contain specific details regarding the support and documentation for either tool. However, as both HeartFlow and iRhythm Technologies are established medical technology companies operating in regulated healthcare environments, it is expected that both offer comprehensive customer support, training, and documentation for their clinician users. Without comparative information on the quality or breadth of these services, a definitive winner cannot be determined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | HeartFlow Analysis | Zio AT ECG Monitoring System |
|---|---|---|
| Primary Diagnostic Focus | Diagnosing and managing coronary artery disease (CAD) | Long-term arrhythmia detection |
| Company | HeartFlow | iRhythm Technologies, Inc. |
| Core Technology/Method | AI-powered 3D modeling of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, Plaque Analysis, Computational Fluid Dynamics (CFD) | Wearable Zio AT patch for continuous ECG recording, FDA-cleared deep-learned AI algorithm (ZEUS System) |
| Data Source | Standard CT scans | Continuous, uninterrupted ECG recording |
| Key Output/Deliverable | Personalized 3D models of coronary arteries, FFRct analysis, Plaque Analysis, Roadmapu2122 Analysis for CCTA reading | Comprehensive end-of-wear reports for clinicians, real-time data transmission |
| Continuous Monitoring Duration | Not specified | Up to 14 days |
Videos
Demos, reviews, and walkthroughs featuring HeartFlow Analysis and Zio AT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring HeartFlow Analysis or Zio AT ECG Monitoring System
Backers
Who funded each tool's parent company.